The definitive guide to gene editing.
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

Nasdaq: EDIT · Cambridge, Massachusetts

Editas Medicine

One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes and rebuilt around a single in vivo cardiovascular candidate.

Preclinical In vivo editing

Pipeline

Where each disclosed programme stands. Stages come from the company's own disclosures on the date shown.

ProgrammeDiseaseTechnologyStage
EDIT-401 Heterozygous familial hypercholesterolemia CRISPR-Cas9 DiscoveryPreclinicalPhase IPhase IIPhase IIIApproved
EDIT-101 (Brilliance) Leber congenital amaurosis 10 CRISPR-Cas9 DiscoveryPreclinicalPhase IPhase IIPhase IIIApproved

Pipeline as recorded in the Atlas on Aug 25, 2026. Companies revise pipelines frequently — verify against the company's own materials and regulatory filings.

In one paragraph

Editas was among the very first CRISPR companies and ran the trial that first injected CRISPR into a human organ. It stopped that programme — the eligible population was too small — and later closed its cell-therapy work too. It now concentrates on one in vivo candidate, EDIT-401, aimed at lowering cholesterol. It is the clearest example in the sector of a company narrowing rather than expanding.

Editas Medicine was founded in 2013 by Feng Zhang, George Church, J. Keith Joung, David Liu and Jennifer Doudna, who departed early. Its EDIT-101 programme was the first in vivo CRISPR administration to a human organ and produced published evidence of vision improvement before being discontinued for population-size reasons. Editas subsequently discontinued its ex vivo assets and focuses on in vivo editing, with EDIT-401 targeting LDLR as its lead candidate.

Sources

Not investment advice This profile is educational information compiled from public disclosures. It is not a recommendation to buy, sell or hold any security, and it is not a view on the company's prospects. Biotechnology is highly speculative and most clinical programmes fail. Full disclaimers →

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.